A blood test showed several cancers in patients who had not yet shown any symptoms. The Pathfinder Study by GRAIL has done what could be a game-changer for cancer diagnosis.
The test, which was conducted on 6,662 people by the healthcare company focused on cancer screening, found cancer in nearly about 1% of the participants.
Conducted on patients aged 50 or above, the findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris.
The test is called Multi-Cancer Early Detection (MCED) test. Researchers explained that the former versions of the test were refined to develop a more accurate test that focuses only on cancer. The previous version also detected fairly common pre-malignant hematologic conditions.
Jeffrey Venstrom, MD, chief medical officer at GRAIL, said that MCED testing detected double the number of cancers than standard screening.
"These included Stage I cancers of the liver, small intestine, and uterus, and Stage II pancreatic, bone, and oropharyngeal cancers," he said in a statement.
Shockingly, 70% of the participants of the study were diagnosed with cancer types that have no standard cancer screening available right now.
In 92 patients, cancer signal was detected and out of these, 35 were diagnosed with 36 cancers.
Researchers claimed that there was a 97% accuracy for the cancer signal origin prediction.
The new test can improve cancer screening and lead to better treatment strategies.
FFI affects an estimated one to two people per million every year
Fresh case reported in Sindh's Jacobabad, taking province's total number of cases in 2024 to 18
Cold season has prominent impact on one’s sleep patterns triggering increased nap time
Premier expresses commitment to winning the fight against polio with help of provinces, global partners
PMDC failed to regulate private medical colleges, says Senator Palwasha Mohammad Zai
Experts reveal post-illness symptoms that indicate if you're still contagious after your sickness goes away
